Dutch cultivated meat company Meatable has acquired the food-focused platform of UK-based Uncommon Bio, including proprietary technology, intellectual property, selected cell lines, and key staff. Financial terms were not disclosed.
The acquisition follows Uncommon Bio’s strategic pivot from cultivated meat to therapeutics, with a focus on lung diseases such as idiopathic pulmonary fibrosis. The company has established a new therapeutics spin-out and is recruiting scientific staff to support its research.
Meatable and Uncommon Bio have both developed techniques that accelerate stem cell differentiation into muscle and fat. Uncommon’s method relies on mRNA to guide pluripotent stem cells, avoiding genome integration and classification as genetically modified. The technology is designed to reduce production costs and speed development timelines.
The addition of Uncommon’s platform expands Meatable’s product capabilities beyond its existing gene-edited approach, supporting diversification across non-GMO and GMO product lines. The company anticipates applying the technology to pork, beef, chicken, lamb, and other high-value meat species, while maintaining regulatory compliance and production efficiency.
Meatable positions the acquisition as a step towards scaling cultivated meat production globally, supplying additional protein without risks associated with livestock diseases, and accelerating market-ready product development across multiple meat types.